Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hemodynamic characterization of a novel neuropeptide Y receptor antagonist.
Tadepalli AS, Harrington WW, Hashim MA, Matthews J, Leban JJ, Spaltenstein A, Daniels AJ. Tadepalli AS, et al. Among authors: spaltenstein a. J Cardiovasc Pharmacol. 1996 May;27(5):712-8. doi: 10.1097/00005344-199605000-00014. J Cardiovasc Pharmacol. 1996. PMID: 8859942
High-affinity neuropeptide Y receptor antagonists.
Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, Spaltenstein A. Daniels AJ, et al. Among authors: spaltenstein a. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9067-71. doi: 10.1073/pnas.92.20.9067. Proc Natl Acad Sci U S A. 1995. PMID: 7568074 Free PMC article.
Synthesis, structure and stability of novel dimeric peptide-disulfides.
Leban JJ, Spaltenstein A, Landavazo A, Chestnut W, Aulabaugh A, Taylor LC, Daniels AJ. Leban JJ, et al. Among authors: spaltenstein a. Int J Pept Protein Res. 1996 Mar;47(3):161-6. doi: 10.1111/j.1399-3011.1996.tb01340.x. Int J Pept Protein Res. 1996. PMID: 8740965
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Wilfret DA, Walker J, Voitenleitner C, Baptiste-Brown S, Lovern M, Kim J, Adkison K, Shotwell B, Mathis A, Moss L, Lee D, Yu L, Gan J, Spaltenstein A. Wilfret DA, et al. Among authors: spaltenstein a. Clin Pharmacol Drug Dev. 2014 Nov;3(6):439-48. doi: 10.1002/cpdd.142. Epub 2014 Oct 20. Clin Pharmacol Drug Dev. 2014. PMID: 27129119 Clinical Trial.
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
Kazmierski WM, Anderson DL, Aquino C, Chauder BA, Duan M, Ferris R, Kenakin T, Koble CS, Lang DG, McIntyre MS, Peckham J, Watson C, Wheelan P, Spaltenstein A, Wire MB, Svolto A, Youngman M. Kazmierski WM, et al. Among authors: spaltenstein a. J Med Chem. 2011 Jun 9;54(11):3756-67. doi: 10.1021/jm200279v. Epub 2011 May 17. J Med Chem. 2011. PMID: 21539377
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A. Furfine ES, et al. Among authors: spaltenstein a. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8. doi: 10.1128/AAC.48.3.791-798.2004. Antimicrob Agents Chemother. 2004. PMID: 14982766 Free PMC article.
Hepatitis C replication inhibitors that target the viral NS4B protein.
Miller JF, Chong PY, Shotwell JB, Catalano JG, Tai VW, Fang J, Banka AL, Roberts CD, Youngman M, Zhang H, Xiong Z, Mathis A, Pouliot JJ, Hamatake RK, Price DJ, Seal JW 3rd, Stroup LL, Creech KL, Carballo LH, Todd D, Spaltenstein A, Furst S, Hong Z, Peat AJ. Miller JF, et al. Among authors: spaltenstein a. J Med Chem. 2014 Mar 13;57(5):2107-20. doi: 10.1021/jm400125h. Epub 2013 Apr 19. J Med Chem. 2014. PMID: 23544424
40 results